What is the TRIDENT Phase III Trial in Glioblastoma?
Based on the provided evidence, there is no TRIDENT phase III trial mentioned or described in any of the guideline or research documents for newly diagnosed glioblastoma. The evidence does not contain any information about a trial with this specific name.
Relevant Phase III Trials in Newly Diagnosed GBM
While TRIDENT is not discussed, the evidence does describe several landmark phase III trials that define current standard of care:
Established Standard of Care Trials
EORTC 26981-22981 (Stupp Protocol) remains the foundational trial establishing radiotherapy with concurrent and adjuvant temozolomide as standard treatment for patients aged 18-70 years with KPS ≥70 1, 2. This regimen provides:
- Concurrent temozolomide (75 mg/m² daily during RT)
- Followed by 6 cycles of adjuvant temozolomide (150-200 mg/m², 5 out of 28 days)
RTOG 0525 demonstrated that dose-dense temozolomide schedules offer no advantage over standard dosing, and extending treatment beyond 6 cycles provides no additional benefit 1.
Recent Controversial Trials
CeTeG/NOA-09 tested lomustine plus temozolomide in MGMT-methylated patients, showing OS benefit but not PFS improvement. However, this involved only 141 patients and remains too immature for definitive recommendations 1, 2. The consensus is to interpret these data cautiously.
CheckMate 498 was a negative phase III trial of nivolumab in MGMT-unmethylated glioblastoma 2.
Common Pitfall
If you are asking about a specific trial acronym not found in standard literature, verify the exact trial name, as it may be:
- A trial in early phases (not yet phase III)
- Known by a different designation
- Institution-specific nomenclature
- Not yet published in major guidelines
The evidence provided covers trials through 2026 publications but contains no reference to TRIDENT.